linjc16/ctgov huggingface dataset:
CART-19 Cells For MRD Positive CD19+ ALL

Study Overview
=================
Brief Summary
-----------------
CART-19 cells has emerged as a powerful targeted immunotherapy, showing striking responses in highly refractory CD19+ acute lymphoblastic leukemia (ALL). This study aims to assess the safety and toxicity of CART-19 cells to patients who are refractory or at highest risk of relapse as defined by MRD+ status.

Official Title
-----------------
CART-19 Cells For Patients With Minimal Residual Disease (MRD) Positive CD19+ Acute Lymphoblastic Leukemia

Conditions
-----------------
Acute Lymphoblastic Leukemia

Intervention / Treatment
-----------------
* Biological: CART-19


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed written informed consent Aged between 1-60 years Patients with MRD positive CD19+ ALL Cardiac: Left ventricular ejection fraction ≥ 50% Adequate renal and hepatic function Performance status: Karnofsky ≥ 70% Exclusion Criteria: Pregnant or lactating females. Any co-morbidity precluding the administration of CART-19 cells.

Ages Eligible for Study
-----------------
Minimum Age: 1 Year
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br>CART-19 cells treated | Biological: CART-19<br>* CART-19 cells treated<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Leukemia free survival |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events that are related to treatment |  | 1 year |
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines

Study Overview
=================
Brief Summary
-----------------
The primary objective of the study is to evaluate the efficacy in wrinkle reduction of a single treatment of three different doses of botulinum toxin compared to placebo, in the treatment of moderate to very severe glabellar frown lines.

Official Title
-----------------
A Multicentre, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Three Doses of Botulinum Toxin in the Treatment of Moderate to Very Severe Glabellar Frown Lines

Conditions
-----------------
Glabellar Frown Lines

Intervention / Treatment
-----------------
* Drug: Botulinum Toxin Type A
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Moderate to Very Severe glabellar lines at maximum frown as assessed by the subject and the Investigator and at least Mild glabellar lines at rest Exclusion Criteria: Any previous treatment with any botulinum toxin Rhytids of the glabellar region that cannot be smoothed out by manually spreading the skin apart Any previous insertion of any permanent or semi-permanent material, hyaluronic acid or collagen fillers to the glabellar region Any history of facial surgery above the lower orbital rim Any planned facial surgery or aesthetic procedure during the study period Ablative skin resurfacing or chemical peels above the lower orbital rim in the previous 12 months or during the study period

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Botulinum Toxin 30 units<br>I.M. injection | Drug: Botulinum Toxin Type A<br> <br> |
| Experimental: Botulinum Toxin 45 units<br>I.M. injection | Drug: Botulinum Toxin Type A<br> <br> |
| Experimental: Botulinum Toxin 60 units<br>I.M. injection | Drug: Botulinum Toxin Type A<br> <br> |
| Placebo Comparator: Placebo<br>I.M. injection | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reduction of glabellar frown line severity on Day 14 following treatment with botulinum toxin | Reduction in glabellar frown line severity is derived separately for the Investigator and the subject assessment, using a validated photo scale, at maximum frown on Day 14. | 14 Days |
Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance.

Study Overview
=================
Brief Summary
-----------------
Genistein Combined Polysaccharide (GCP) may play a role as a secondary chemopreventive agent in the treatment of localized prostate cancer.

Official Title
-----------------
Effects of a Genistein Concentrated Polysaccharide (GCP) on Patients With a Diagnosis of Prostate Cancer on Active Surveillance.

Conditions
-----------------
Prostate Cancer

Intervention / Treatment
-----------------
* Drug: Placebo
* Drug: GCP - Genistein Combined Polysaccharide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants must be male and have a pathological diagnosis of prostate cancer Pathological diagnosis of prostate cancer must be confirmed and on file with CRA prior to study entry. No treatment (surgery, radiation, or hormones) prior to study entry. PSA between 2.0 and 10.0 ng/ml. If PSA is >10.0, patient must have been on Active Surveillance for 12 months prior to study initiation. No known allergy to soy or soy products. The patient is not currently taking more than 2 grams of genistein a day in nutritional or diet enhancing supplements (OTC supplements). Participant has not been on any previous GCP clinical trial. Normal Chemistry values prior to study entry. Exclusion Criteria: No pathological documentation of prostate cancer. Prior treatment for prostate cancer. PSA >10.0 ng/ml but not on Active Surveillance for 12 months. Allergy to soy or soy products. Abnormal chemistry values.
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: A<br>A=Placebo ARM of Study | Drug: Placebo<br>* 10 Placebo Capsules taken orally every day.<br>* Other names: Placebo capsules (contain cellulose only);|
| Active Comparator: B<br>B=GCP Capsules. Ten 500 mg capsules per day for a total of 5 grams a day. | Drug: GCP - Genistein Combined Polysaccharide<br>* Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease in PSA levels in men on GCP |  | 6 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Increased PSA Doubling Time (PSADT)in men on GCP. |  | 6 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Localized, Prostate, Cancer
Phase III Randomized, Placebo-Controlled, Crossover Study of Soy Protein Isolate for Hereditary Hemorrhagic Telangiectasia

Study Overview
=================
Brief Summary
-----------------
OBJECTIVES: I. Evaluate migraine prophylaxis with soy protein isolate in patients with hereditary hemorrhagic telangiectasia. II. Assess whether soy protein isolate reduces the frequency and severity of epistaxis and gastrointestinal bleeding in these patients.

Detailed Description
-----------------
PROTOCOL OUTLINE: This is a randomized study. One group of patients is treated with soy protein isolate for 12 weeks. The control group receives a placebo for 12 weeks. Patients cross to the alternate group following a 4-week washout.

Conditions
-----------------
Hereditary Hemorrhagic Telangiectasia

Intervention / Treatment
-----------------
* Drug: soy protein isolate


Participation Criteria
=================
Eligibility Criteria
-----------------
Hereditary hemorrhagic telangiectasia (HHT) with 2 of the following: First-degree relative with HHT History of recurrent epistaxis or gastrointestinal bleeding Three or more skin telangiectasia Migraine headache meeting International Headache Society criteria 3 or more times a month for more than 1 year No pattern of daily headaches No severe head trauma No onset of headaches after 50 years of age At least 1 month since migraine prophylaxis At least 1 month since any of the following medications: Beta blockers; Calcium channel blockers; Divalproex sodium; Tricyclic antidepressants; Selective serotonin re-uptake inhibitors Concurrent regular treatment for migraine and gastrointestinal hemorrhage allowed Creatinine no greater than 2.5 g/dL No allergy to soy No pregnant women No women with intent to become pregnant

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: soy protein isolate|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
genetic diseases and dysmorphic syndromes, hematologic disorders, hereditary hemorrhagic telangiectasia, rare disease
An Observational Study of Dry Eye Prior to Laser-Assisted in Situ Keratomileusis (LASIK) Therapy

Study Overview
=================
Brief Summary
-----------------
This is an observational, study of dry eye in patients at the consultation visit prior to LASIK surgery. There is no treatment administered or intervention during the study.

Conditions
-----------------
Dry Eye Syndromes

Intervention / Treatment
-----------------
* Other: No Treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Attending an ophthalmology consultation for LASIK Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients Attending Consultation for LASIK<br>Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study. | Other: No Treatment<br>* Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Patients in Each Category of the Dry Eye Workshop Severity (DEWS) Scale | The severity of each patient's dry eye was classified by the physician according to the DEWS scale. Categories are: mild and/or episodic, occurs under environmental stress; moderate episodic or chronic, stress or no stress; and severe frequent or constant without stress | Day 1 |
Effects of Ritalin on Postural Stability of Hyper Active Children

Study Overview
=================
Brief Summary
-----------------
Experimental design overview The proposed project is a prospective experimental study design. Children (age <15) suffer from attention deficit hyperactivity disorder (ADHD) that their Parents willing to participate in the study will be tested with well-established measuring techniques of Balance control before and 1 hour after taking of Methylphenidate (Ritalin) in the movement and Rehabilitation Laboratory at BGU. An automated algorithm will be used to extract standardized stabilogram-diffusion parameters from each of the COP data sets collected during quiet standing. These parameters include diffusion coefficients, critical displacement, critical time and scaling exponents for both lateral and anterior-posterior sway directions (Collins & De Luca, 1993). For each of the conditions (before and 1 hour after the use of Ritalin) in three task conditions single task; dual task (concentrating and identifying specific music); and just Listening to a relaxing music. Participants will be required to stand on the platform 10 times for 30 s. For each trial, they will be instructed to sway as little as possible.

Official Title
-----------------
Effects of Methylphenidate on Postural Stability of Children Suffer From Attention Deficit Hyperactivity Disorder (ADHD) Under Single and Dual Task Conditions.

Conditions
-----------------
Attention Deficit Disorder With Hyperactivity

Intervention / Treatment
-----------------
* Drug: Ritalin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 6-12 years old Diagnosed as ADHD childrens by a neurologist Taking methylphenidate (Ritalin) Exclusion Criteria: Children who suffer from CP, or other neurological disease Children who suffer from psychiatric state Children who suffer from orthopedic condition (1/2 a year after a fracture in the lower limb)

Ages Eligible for Study
-----------------
Minimum Age: 6 Years
Maximum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Ritalin|The effect of ritalin on postural stability of ADHD childrens will be measured using RCT study design|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postural sway measures |  | Time 1: pre test' and hour later time 2: post testinng proceedure | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
attention deficit hyperactivity disorder (ADHD), Dual tasking, Postural Control, Methylphenidate (Ritalin), The focus of the study is To explore the effects of Ritalin on postural control in ADHD Children, during single and dual task conditions.
Predicting Rupture of AAA by Anatomic and Hemodynamic Markers

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to investigate imaging findings, which can help us to predict factors contributing to abdominal aortic aneurysm growth and rupture.

Official Title
-----------------
Predicting Rupture of Abdominal Aortic Aneurysm (AAA) by Anatomic and Hemodynamic Markers From In-vivo and In-vitro Imaging

Conditions
-----------------
Aortic Aneurysm, Abdominal

Intervention / Treatment
-----------------
* Other: Medical imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals between 18 and 80 years old receiving medical care at University of Minnesota Medical Center who have a normal aorta CTA within the previous year Or patients with known AAA with growth rate of 0-0.2 cm/year Or patients with known AAA with growth rate of greater than 0.5 cm/year. Exclusion Criteria: Subjects with ferromagnetic implants Penile implant Hip replacement History of shrapnel or shot gun injury Body mass index ≥ 30 Cardiac pacemakers Severe claustrophobia Large tattoos on the torso

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Medical imaging|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Imaging findings correlating with abdominal aortic aneurysm growth and rupture |  | 1 year |
Empirical Mode Decomposition in the Electroencephalogram

Study Overview
=================
Brief Summary
-----------------
Bispectral index (BIS), a standard monitor for perioperative monitor of patient's conscious level, is a noninvasive medical technique for monitoring and recording the electrical activity of brain.

Detailed Description
-----------------
The electroencephalogram and BIS data have lots of information. Fourier transformation to decompose EEG was first applied on the EEG signaling until now. The disadvantages of Fourier transformation is hard to deal with physical signals, which was modulated by autonomic system and factors. The Hilbert-Huang transform (HHT) was proposed to decompose EEG signal into intrinsic mode functions (IMF) since 2004. HHT can obtain instantaneous frequency data and work well for data that is nonstationary and nonlinear. HHT have been applied for wild ranges, not only in the analysis of arrhythmia for medical and public health fields, but also in the earthquake detection and earth physics detection…etc. The relationship between frontal EEG patterns and general anesthesia remain poorly understood. It can only say that the increase in frontal EEG power and shift power to lower frequencies during general anesthesia from publications. The investigators are going to compare the EEG signal between generations, try to find the difference in aging using empirical mode decomposition method.

Official Title
-----------------
Empirical Mode Decomposition in the Electroencephalogram During General Anesthesia Between Generations

Conditions
-----------------
Depth of Anesthesia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20-40y/o or over 60y/o Scheduled for low risk general anesthesia Suitable for surgery after interviewed by anesthesiologist Exclusion Criteria: Not suitable for general anesthesia High risk patient Allergic to the EEG sensor

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Younger<br>20-40 years old patients | |
| Elderly<br>over 60 years old patients | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| EEG power calculation | The investigator use root mean square energy to calculate EEG power. | During the operation time. |
Randomized Trial Of Tinnitus Retraining Therapy

Study Overview
=================
Brief Summary
-----------------
Millions of Americans suffer from tinnitus. However, there is no widely accepted treatment that has been shown to be effective in controlled investigations. The purpose of this study is to evaluate the effectiveness of Tinnitus Retraining Therapy (TRT). This study will investigate the contributions of counseling, the use of hearing aids and sound generators, and the importance of setting masking noise to a particular level. All groups will receive the same Counseling. In pilot studies we have developed a picture-based counseling protocol. The results of this study will determine if TRT is more effective than masking or counseling alone.

Official Title
-----------------
Randomized Trial Of Tinnitus Retraining Therapy

Conditions
-----------------
Tinnitus

Intervention / Treatment
-----------------
* Other: Counseling and Sound Therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Have experienced tinnitus for at least 4 months. Have the ability to participate in research. Exclusion Criteria: Have a treatable otological disorder. Are involved in litigation. Have or are suspected of having a serious psychiatric problem.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: 1<br>Counseling plus everyday noise type 1 | Other: Counseling and Sound Therapy<br>* Tinnitus counseling and sound therapy<br>|
| Other: 2<br>Counseling plus static noise type 2 | Other: Counseling and Sound Therapy<br>* Tinnitus counseling and sound therapy<br>|
| Other: 3<br>Counseling plus static noise type 3 | Other: Counseling and Sound Therapy<br>* Tinnitus counseling and sound therapy<br>|
| Other: 4<br>Hearing aid and counseling plus everyday noise type 1 | Other: Counseling and Sound Therapy<br>* Tinnitus counseling and sound therapy<br>|
| Other: 5<br>Hearing aid and counseling plus static noise type 2 | Other: Counseling and Sound Therapy<br>* Tinnitus counseling and sound therapy<br>|
| Other: 6<br>Hearing aid and counseling plus static noise type 3 | Other: Counseling and Sound Therapy<br>* Tinnitus counseling and sound therapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Iowa Tinnitus Handicap Questionnaire |  | 18 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tinnitus measures |  | 18 months |
Pilot Trial to Elaborate a Cutaneous Antigen Neutralization Test in Patients Suffering From Rhinoconjunctivitis

Study Overview
=================
Brief Summary
-----------------
To find a test to elaborate a parameter for specific immunotherapy in allergic patients

Official Title
-----------------
Pilot Trial to Elaborate a Cutaneous Antigen Neutralization Test in Patients Suffering From Rhinoconjunctivitis Due to Grass Pollen During Immunotherapy

Conditions
-----------------
Allergy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18 and 65 Signed informed consent SIT 2000/2001 10 patients with SIT with a good result- 10 patients with bad results Exclusion criteria: Pregnancy and breastfeeding

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |